Oncology

Ceenu (Lomustinum)

Ceenu has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in the folowing:
Brain tumor_both primary and metastatic, in patients who have already received appropiate surgical and/or radiotherapeutic procedures.
Hodgkin's disease- secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
Possible uses: bronchial cancer, non-hodgkin's lymphomas, melanoma, nephrocarcinoma, gastrointestinal tumor. Laboratory Ceenu/Lomustine:Brystol-Myers Squibb